the ATTAIN question that gets asked weekly, answered properly
Something I keep coming back to: the ATTAIN question that gets asked weekly, answered properly.
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
The analytical point, which this board keeps getting wrong by importing habits from the peptide side.
For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.
So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
Right, and comparing milligrams between a small molecule and a peptide is meaningless in either direction.
Right, and comparing milligrams between a small molecule and a peptide is meaningless in either direction.
Agreed, and it is why the oral peptide comparison keeps misleading people.
Are you comparing doses across a small molecule and a peptide?
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
daily dosing, not weekly, so the exposure profile is different
Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.
do not assume reconstitution intuitions apply, there is nothing to reconstitute
phase 3 is where the comparison becomes fair
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
What analytical method was used — this is not the usual peptide assay question?
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Spent an evening reading about small-molecule agonism at a peptide receptor.
cloudy_vial_carol is right that milligram comparisons across classes tell you nothing.
Has anyone here seen independent identity testing on this?
Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.
Corrected a cross-class dose comparison in the title. The body is untouched.
Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.
Went looking for independent testing on this and found essentially nothing, which was clarifying.